Kangchen Pharmaceutical (603590.SH): KC1036 in combination with PD-1 antibody and platinum-based chemotherapy approved for clinical trials in first-line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma.

Zhtng Cijng APP, Kngchn Yoy (603590.SH) fb gnggo, jnr, gngs shudo guji yopn jind gunl j hk zhf de huxu 1 li chungxn yo KC1036 pin guny "KC1036 linh PD-1 kngt h hn b hulio yxin zhlo wnq ffng hu zhunyxng shgun qunci" de lnchu shyn tngzhsh, bng jing y jnr kizhn lnchu shyn. Zhitong Finance APP news, Kangchen Pharmaceutical (603590.SH) announced that the company has recently received a clinical trial notification for the innovative chemical class 1 drug KC1036 tablets approved and issued by the National Medical Products Administration for the "Clinical trial of KC1036 combined with PD-1 antibodies and platinum-containing chemotherapy for first-line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma," and will conduct clinical trials in the near future.